<DOC>
	<DOC>NCT00367146</DOC>
	<brief_summary>The use of CNIs (CSA or FK) as primary immunosuppressive drugs after pediatric liver transplantation is one of the main causes of chronic kidney disease in these patients in the long term. The study objective is the evaluation of safety of a modification in immunosuppression from a dual-immunosuppression (CSA or FK plus steroids) to a triple immunosuppression (MMF plus CSA (reduced dosage) plus steroids.</brief_summary>
	<brief_title>MMF After Pediatric Liver Transplantation</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency, Chronic</mesh_term>
	<criteria>patients after pediatric liver transplantation no acute rejections for the last half year concomitant malign disease (e.g. ptld) neutropenia (granulocytes &lt;1000/Âµl) systemic infection thrombopenia (&lt;80/nl)</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>July 2007</verification_date>
	<keyword>liver transplantation</keyword>
	<keyword>children</keyword>
	<keyword>immunosuppression</keyword>
	<keyword>mycophenolatmofetil</keyword>
	<keyword>calcineurin inhibitor</keyword>
	<keyword>kidney disease</keyword>
</DOC>